These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9337675)

  • 1. 5-HT3 receptor antagonists: differences and similarities.
    Roila F; Ballatori E; Tonato M; Del Favero A
    Eur J Cancer; 1997 Aug; 33(9):1364-70. PubMed ID: 9337675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.
    Perez EA
    J Clin Oncol; 1995 Apr; 13(4):1036-43. PubMed ID: 7707101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    Cancer Invest; 2000; 18(2):163-73. PubMed ID: 10705879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.
    Perez EA
    Drug Saf; 1998 Jan; 18(1):43-56. PubMed ID: 9466087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research on antiemetics: an Italian model of success].
    Roila F
    Tumori; 1998; 84(1 Suppl):S3-11. PubMed ID: 9617377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.
    Del Favero A; Roila F; Tonato M
    Drug Saf; 1993 Dec; 9(6):410-28. PubMed ID: 7510495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Simpson K; Spencer CM; McClellan KJ
    Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
    Ossi M; Anderson E; Freeman A
    Oncology; 1996 Jun; 53 Suppl 1():78-85. PubMed ID: 8692556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
    Hesketh PJ
    Support Care Cancer; 1994 Sep; 2(5):286-92. PubMed ID: 8000724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there differences among the serotonin antagonists?
    Tonato M; Roila F; Del Favero A
    Support Care Cancer; 1994 Sep; 2(5):293-6. PubMed ID: 8000725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of experience with ondansetron and granisetron.
    Aapro MS
    Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
    Morrow GR; Hickok JT; Rosenthal SN
    Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.